Joshua Brody: Awesome Efficacy of Bispecific Antibody Immunotherapy
Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn about a recent paper by Taylor R Brooks et al. published in ASH Publications:
“Important work by Drs. Brooks and Hill Cleveland Clinic with docs Mount Sinai Health System and others, reporting awesome efficacy of bispecific antibody immunotherapy, but also the somewhat scary antigen escape in >80% of relapsing patients.”
Title: Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Authors: Taylor R Brooks, Emily C Zabor, Yohanna Bedelu, Xi Yang, Yasmin H. Karimi, Adrienne N Nedved, Yucai Wang, Nikita K Dave, Daniel J. Landsburg, Kelsey Baron, Boyu Hu, Daniel Trotier, Priyanka A Pophali, Jordan Miller, PharmD, Natalie S. Grover, Catherine Reinert, Ajay Major, Tenley Schwarz, Krish Patel, Kiarash Salafian, Emily C. Ayers, Suchitra Sundaram, Joshua D. Brody, Marshall McKenna, Yun Kyoung Ryu Tiger, Megan Sears-Smith, Nilanjan Ghosh, Chelsea Peterson, Cyrus Khan, Sean P Bliven, Mayur Narkhede, Alyssa Gibson, Justin Kline, Javier Munoz, Rodolfo Garza Morales, Carrie Ho, Stephen D Smith, Alex Niu, Francisco J. Hernandez-Ilizaliturri, Fadzai Chinyengetere, Sandeep S. Dave, Nayef Abdel-Razeq, Muhamad Alhaj Moustafa, Paolo Caimi, Brian T. Hill
More posts featuring Joshua Brody.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023